ALMS — Alumis Inc.

Is ALMS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Alumis Inc. (ALMS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $23.99. The rating moved from Neutral to Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

Alumis Inc. (ALMS) sits in a sector benefiting from validated gene-therapy approvals and growing demand for specialized biologics manufacturing and testing services. Near-term sentiment is steady, with no major macro or geopolitical drivers evident; this sets a neutral market backdrop where company-specific operational updates or contract/partnership announcements are likely to move the stock. The investment case rests on capturing CDMO/CRO demand and demonstrating execution and commercial traction. Key unknowns include up-to-date financials and cash runway, making current assessment dependent on thematic tailwinds rather than audited disclosures. Watch for near-term catalysts such as earnings commentary, partnership or capacity announcements, and any filing activity that clarifies revenue and margin trends.

Key factors

  • Favorable sector tailwinds: validated gene-therapy approvals and growing demand for viral-vector manufacturing, fill/finish, and specialized CDMO/CRO services lift addressable market for suppliers.
  • Market environment in the short window is steady without major macro shocks, allowing company-specific news or operational updates to drive price action.
  • Potential M&A and elevated biotech/pharma multiples could create strategic interest in companies with relevant capabilities or assets.
  • Growth optionality through partnerships, contract wins, or commercialization-readiness that would materially increase revenue visibility if announced.
  • Limited adverse headlines or geopolitical developments in the observation window, reducing event-driven downside near-term.
  • Lack of recent public filings or detailed financial disclosures in the provided dataset increases reliance on thematic and market-readthrough analysis rather than company-specific fundamentals.

Risks

  • Material information gap: no EDGAR/filing data available to verify revenue, profitability, cash runway, or debt profile.
  • Regulatory and clinical risk inherent to biologics / gene-therapy supply chains and any affiliated product pipelines.
  • Execution risk for scaling manufacturing or winning CDMO contracts; capacity and quality issues can erode margin and credibility.
  • Competitive pressure from established CDMO/CRO providers and new entrants pursuing the same gene-therapy supplier demand.
  • Valuation sensitivity and liquidity risk: lack of broad social sentiment data and low trading interest can amplify volatility on news.
  • Payer and reimbursement dynamics indirectly affecting end-market demand (for therapeutics) and buyer budgets for related services.

See today's live rating, score and targets

Members see the live hourly rating for ALMS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.